Experts discuss the decision-making factors and real-world challenges that shape treatment selection in diffuse large B-cell lymphoma (DLBCL) patient care. They focus on how efficacy data, safety profiles, and patient factors influence treatment choices, and the implementation challenges encountered when introducing newer regimens into practice.
Experts discuss how disease progression impacts patients with diffuse large B-cell lymphoma (DLBCL) and strategies for managing progressive disease based on first-line therapy selection, incorporating insights from the POLARIX 5-year subsequent treatment data and highlighting quality-of-life considerations that influence treatment decisions.
Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.
Yago Nieto, MD, PhD, discusses AFM13, how it works, and its effect as a bispecific antibody that targets CD30 and CD16.
John L. Marshall, MD, discusses the sequencing of targeted therapy for refractory metastatic colorectal cancer.
David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard chemoradiotherapy for patients with limited-stage small cell lung cancer.
Julie Gralow, MD, FACP, FASCO, discusses the strategies and policy changes implemented by ASCO to address the oncology workforce shortage.
Seth Wander, MD, PhD, discusses the extended survival with elacestrant in a real-world, which was longer than the randomized phase 3 trial data.
Panelists discuss the management of treatment-associated interstitial lung disease (ILD) and pneumonitis, emphasizing diagnostic strategies, therapeutic options, and patient monitoring.
Panelists discuss strategies for managing adverse events (AEs) related to antibody-drug conjugates (ADCs), focusing on prevention, early detection, and treatment of these effects.
Cedric Pobel, MD, discusses how the results of the PEACE-1 trial support the use of radiotherapy plus standard of care and abiraterone in low-volume metastatic castration-sensitive prostate cancer.
John Seymour, MBBS, FRACP, PhD, explains why BCL-2 was considered an undruggable target for so long and what led to the development of effective BCL-2 inhibitors.
A panelist discusses how steroid therapy remains the cornerstone of acute graft-vs-host disease (GVHD) treatment, with treatment protocols typically starting with prednisone at doses ranging from 1 to 2 mg/kg/day depending on disease severity, though optimal dosing strategies continue to be refined through clinical research.
Hedyeh Ebrahimi, MD, MPH, discusses updated data from a phase 1 study of CBM588, cabozantinib, and nivolumab in metastatic renal cell carcinoma.
Pat Gulhati, MD, PhD, discusses findings from a comprehensive analysis of genetic, immunological, and signaling pathway variations in pancreatic cancer.
Enriqueta Felip, MD, PhD, discusses the phase 3 3475A-D77 study of subcutaneous pembrolizumab plus chemotherapy in metastatic non–small cell lung cancer.
Deborah Wong, MD, PhD, discusses the toripalimab combination that is now considered standard of care in nasopharyngeal cancer.
Hamlet Gasoyan, MD, discusses some of the common challenges that oncologists face when getting patients started on more costly oral treatments for multiple myeloma.
Seth Wander, MD, PhD, discusses the tolerability of selective estrogen receptor degraders and next-generation anti-estrogen agents in breast cancer.
Experts discuss polatuzumab’s effectiveness across germinal center B-cell (GCB) and activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL) subgroups, including updates to published data. They also explore how different molecular classification methods compare in clinical practice to guide treatment selection, with insights on differential responses across specific molecular or clinical subgroups.
Experts discuss clinical experience with established and emerging treatment approaches in diffuse large B-cell lymphoma (DLBCL), including R-CHOP and polatuzumab-based regimens, and the factors guiding treatment selection for first-line DLBCL, along with observed outcomes across different patient subgroups.
Matt Galsky, MD, discusses the phase 3 NIAGARA trial that led to the recent FDA approval of durvalumab in muscle-invasive bladder cancer after radical cystectomy.
Meredith McKean, MD, MPH, discusses the background and goals from the recent long-term follow-up of a phase 1 study evaluating the combination of fianlimab and cemiplimab in advanced melanoma.
Julie Gralow, MD, FACP, FASCO, addresses ways to combat the oncology workforce shortage.
Uday R. Popat, MD, discusses promising findings from a phase 2 trial evaluating the JAK inhibitor itacitinib combined with post-transplant cyclophosphamide and tacrolimus for graft-vs-host disease prevention.
Panelists discuss how lenvatinib has significantly impacted the systemic therapy landscape for hepatocellular carcinoma (HCC) across different stages. As a first-line treatment, it offers a viable alternative to sorafenib, demonstrating noninferior overall survival with improved progression-free survival and response rates. Its role extends to combination regimens and advanced-stage disease management.
Panelists discuss how, when a patient progresses to second-line therapy, key considerations include prior treatment response, toxicity, patient comorbidities, and therapeutic goals. Lenvatinib shows potential beyond first-line treatment, offering efficacy in patients progressing on systemic therapies, with emerging data supporting its role in treatment sequencing.
Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab and chemotherapy for the treatment of patients with HER2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
John M. Burke, MD, shares his tips for offering bispecific antibody therapy in a community setting.
John M. Burke, MD, provides practical tips for administering mosunetuzumab in a community setting.